GERON CORP (GERN)
Health Care · Oncology / hematologic malignancies biopharmaceutical · NASDAQ
First-in-class telomerase inhibitor company with FDA-approved RYTELO for myelodysplastic syndromes, now expanding into myelofibrosis with Phase 3 clinical data pending.
What GERON CORP does
Geron is a commercial-stage biopharmaceutical company developing telomerase inhibitors to treat blood cancers. Its first-in-class product, RYTELO (imetelstat), was FDA-approved in June 2024 for lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia and received European Commission approval in March 2025. The company is expanding RYTELO's reach through commercial launch in the U.S. and selected EU markets, while advancing a Phase 3 trial (IMpactMF) evaluating imetelstat in myelofibrosis, a more advanced form of blood cancer.
Themes: Blood cancer / hematologic malignancies, Telomerase inhibitors, Myelodysplastic syndromes (MDS) treatment, Myelofibrosis treatment, Orphan/rare blood disorders
Fundamentals
- Price$1.52 as of 2026-08-24 close
- Market cap$977M as of 2026-08-24
- 1-year return+4.1% 2025-08-22 close $1.46 → 2026-08-24 close $1.52
- P/En/a negative earnings
- Net margin-33.0% as of 2026-08-24
- Gross margin+96.6% as of 2026-08-24
- ROE-29.3% as of 2026-08-24
- Debt / equity1.14 as of 2026-08-24
- Revenue growth (YoY)+24.4% as of 2026-08-24
- Revenue CAGR (3y)-2.2% SEC XBRL
- Beta1.13 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How GERN compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How GERON CORP looks technically
GERON CORP (GERN) is trading 7.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 40 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 13 trading days ago. It is 24.4% below its highest point of the past year. Trading volume is unusually light — only about 45% of its 30-day average.
Trend
9
| Distance from the 200-day | it is trading 7.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +7.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.41 | $1.41 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.42 | $1.42 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 1.65. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 40 trading days ago — a "death cross", a bearish long-term signal | 40 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 7.0% above | +7.0% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend) | 16.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30) | 52.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($1.31 to $1.65) — its "stochastic" reading is 62 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 61.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $2.01 | $2.01 |
|---|---|---|
| From the 52-week high | it is 24.4% below its 52-week high (its highest price of the past year) | -24.4% |
| Above the 52-week low | it is 46.2% above its 52-week low (its lowest price of the past year) | +46.1% |
| Below the 52-week high | it is 24.4% below its highest point of the past year | 24.4% |
| Since a 20-day breakout | it made a new 20-day high about 13 trading days ago | 13 sessions |
| Since a 55-day breakout | it made a new 55-day high about 13 trading days ago | 13 sessions |
| All-time high | its highest closing price on record is $11.51 (set on 2005-09-12) | $11.51 |
| Given back of the 52-week move | over the past year its closes ranged ($1.07 to $1.95), and it has given back around half of its rise from last year’s low — 49% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.38 to $1.41. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 48.9% |
| From the all-time high | it is 86.8% below its all-time high | -86.8% |
| Nearest price level | it is trading 2.8% above a support level at $1.48 — a price it turned at 7 times since 2025-04-28, most recently on 2026-06-25. Since 2024-08-21 it has 7 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.8% |
| All-time low | its lowest closing price on record is $0.75 (set on 2020-03-16) | $0.75 |
| Above the all-time low | it is 102.7% above its all-time low | +102.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 57th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0904 between its high and its low — about 6.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0904 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.28 and $1.69 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.28 – $1.48 – $1.69 |
| Typical daily range (% of price) | its price moves about 6.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is trading 1.1 daily ranges above its 200-day average price (7.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 45% of its 30-day average | 0.45× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.7% |
|---|---|---|
| Open gap | it gapped 2.2% above the previous close 12 sessions ago and has not traded back through the level it left behind at 1.34 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.2% |
| Gap filled | a 2.6% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -4.4% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 3.2 percentage points (the stock gained 5.6% while the market gained 2.3%) | +3.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 17.5 percentage points (the stock gained 20.6% while the market gained 3.1%) | +17.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 30.2 percentage points (the stock lost 19.1% while the market gained 11.1%) | -30.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 14.2 percentage points (the stock gained 6.3% while the market gained 20.5%) | -14.2% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.2% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 1.0% of the share price, which is taken to mean a barrier that gives way easily. | +7.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $1.50 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +1.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $1.57 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | -3.0% |
Price levels it has turned at before
GERN last closed at $1.52 on 2026-08-21. Since 2024-08-21 it has turned at 7 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.48 | Support | 2.8% below the last close | turned there 7 times · 2025-04-28 to 2026-06-25 |
| $1.45 | Support | 4.8% below the last close | turned there four times · 2025-02-26 to 2026-03-19 |
| $1.37 | Support | 10.1% below the last close | turned there three times · 2025-07-23 to 2026-07-14 |
| $3.10 | Resistance | 104.3% above the last close | turned there twice · 2025-01-24 to 2025-02-05 |
| $4.22 | Resistance | 177.5% above the last close | turned there twice · 2024-09-23 to 2024-11-27 |
| $4.81 | Resistance | 216.3% above the last close | turned there twice · 2024-08-30 to 2024-09-20 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $1.65.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 4 trading days, since 2026-08-18.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · trendless / choppy (low ADX) · lagging the market · Trading at this year’s average price paid (anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.60 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$4.25 range $3.00 – $6.00; median $4.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for GERN
- Consensus EPS estimate-$0.01 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Commercial execution risk: RYTELO is an early-stage commercialization with limited product revenue history; patient adoption in MDS may be slower than projected given physician unfamiliarity with telomerase inhibition mechanism and safety management requirements.","Clinical development risk: The Phase 3 IMpactMF trial in myelofibrosis is not expected to have interim OS data until H2 2026 and final analysis in H2 2028; failure or delays could limit revenue expansion beyond MDS.","Reimbursement and market access risk: European commercialization depends on securing favorable reimbursement and HTA outcomes; the company relies on third-party partners for EU commercialization and distribution, creating execution dependency."]
What changed in the latest 10-Q
AI-assisted comparison of GERN's 10-Q filed 2026-05-06 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Added specific language about market segments: 'including second-line ESA ineligible patients regardless of prior treatment or RS status and first-line ESA ineligible patients' (newer filing, 2026-05-06)
- Added details about Named Patient Programs (NPPs): 'To enable paid access to patients outside the U.S. through approved Named Patient Programs, or NPPs, in 2025, we partnered with Tanner Pharma, a distributor with broad global reach to support patient access. To date, product revenue pursuant to NPPs have been minimal.' (newer filing, 2026-05-06)
- Added reference to 2025 Form 10-K filed on March 2, 2026 (newer filing, 2026-05-06)
- Added 'cash generated from sales of RYTELO' to financing sources list (newer filing, 2026-05-06)
- Removed:
- Removed language 'We do not plan to commercialize RYTELO independently in the EU (or in any other regions outside of the U.S. where RYTELO may be approved for marketing in the future). Accordingly, we plan to' from EU commercialization discussion (older filing, 2025-11-07)
- Removed reference to 2024 Form 10-K filed on February 27, 2025, replaced with 2025 Form 10-K (newer filing, 2026-05-06)
- Reworded:
- Changed 'appear throughout the Report' to 'appear throughout this Report' in Forward-Looking Statements section (newer filing, 2026-05-06)
- Changed NCCN Guidelines reference from 'NCCN Guidelines ® ,' to 'NCCN Guidelines®,' (spacing/formatting change, newer filing, 2026-05-06)
- Changed 'position RYTELO to potentially compete for significant market segments in lower-risk MDS.' to 'position RYTELO to potentially compete for significant market segments in lower-risk MDS, including second-line ESA ineligible patients regardless of prior treatment or RS status and first-line ESA ineligible patients.' (newer filing, 2026-05-06)
- Changed phrasing from 'At this time, we do not plan to commercialize RYTELO independently in the EU... Accordingly, we plan to work with experienced third parties' to 'At this time, we are working with experienced third parties' (newer filing, 2026-05-06)
- Changed 'As of the end of September 2025, the trial has reached full enrollment' to 'As of September 2025, the trial was fully enrolled' (newer filing, 2026-05-06)
- Changed 'Based on our current assumptions for event (death) rates in the trial' to 'Based on our current planning assumptions for event (death) rates in the trial' (newer filing, 2026-05-06)
- Changed cash position from 'approximately $421.5 million in cash, cash equivalents, restricted cash and marketable securities' as of September 30, 2025 to 'approximately $341.0 million in cash, cash equivalents, restricted cash and marketable securities' as of March 31, 2026 (newer filing, 2026-05-06)
- Changed accumulated deficit from 'approximately $1.8 billion' as of September 30, 2025 to 'approximately $1.9 billion' as of March 31, 2026 (newer filing, 2026-05-06)
- Notes:
- Loan agreement description was truncated in both filings at similar points; comparison limited to available text
- Older filing text also appears truncated at end of Royalty Pharma Agreement section
Risk Factors
- Added:
- New risk factor added (2026-05-06): 'Our strategic restructuring plan and the associated workforce reduction implemented in December 2025 may not result in anticipated savings and long-term value creation, could result in total costs and operating expenses that are greater than expected and could disrupt our business.'
- New risk factor added (2026-05-06): 'Our relationships with healthcare providers, including physicians and third-party payors, the methods by which we promote RYTELO, and the content of our promotional materials and programs, are subject to applicable promotional, anti-kickback, fraud and abuse, and other healthcare laws and regulations, and our failure to comply with these laws could expose us to criminal sanctions, civil penalties, exclusion from federal health care programs, contractual damages, reputational harm and may adversely affect our business and financial results.' (under Risks Related to Compliance with Healthcare Laws)
- New risk factor added (2026-05-06): 'Risks Related to Our Indebtedness and Royalty Payment Obligations' section with bullet: 'Our level of indebtedness and debt service obligations could adversely affect our financial condition and may make it more difficult for us to fund our operations, including by limiting our operating and financial flexibility.'
- Removed:
- Removed (2025-11-07): 'Although we have established commercial operations and sales, marketing and distribution infrastructure for RYTELO, we have limited experience in sustaining and scaling these operations and our commercialization efforts may be unsuccessful or less successful than anticipated.' [replaced by similar but reworded bullet in 2026-05-06]
- Removed (2025-11-07): 'We have limited experience as a commercial company and our sales, marketing, and distribution of RYTELO may be unsuccessful or less successful than anticipated.'
- Removed (2025-11-07): 'If we do not maintain acceptable prices or adequate reimbursement for RYTELO, the use of RYTELO could be severely limited.'
- Removed (2025-11-07): 'To be commercially successful, RYTELO must be accepted by the healthcare community, which can be slow to adopt or unreceptive to new technologies and products.'
- Removed (2025-11-07): 'If the market opportunities for RYTELO are smaller than we believe, our revenue may be adversely affected, and our business may suffer.'
- Removed (2025-11-07): 'We face competition from existing products, product candidates and technologies, and competitors may develop new products and technologies.' [consolidated into single bullet in 2026-05-06]
- Removed (2025-11-07): 'We rely on a select network of third party distributors, specialty pharmacies and other vendors to distribute RYTELO in the U.S., and any failure by such distributors, specialty pharmacies and vendors could adversely affect our revenues, financial condition, or results of operations.'
- Removed (2025-11-07): 'We will be subject to pricing, drug marketing, post-market and reimbursement regulations in the European Union, or EU, which may materially affect our ability to commercialize and receive reimbursement coverage for RYTELO in the EU.' [reworded in 2026-05-06]
- Removed (2025-11-07): 'We may be unable to obtain regulatory approval to commercialize RYTELO in any other jurisdictions or for any new indications, or may experience significant delays in doing so, any of which could severely and adversely affect our business and business prospects, and might cause us to cease operations.'
- Removed (2025-11-07): 'The FDA, the Department of Justice, or DOJ, and other regulatory authorities actively enforce regulations related to the promotion and advertisement of pharmaceutical products, and if we were found to have violated the Food, Drug and Cosmetic Act, we could be subject to significant civil, criminal and administrative penalties.' [replaced with more detailed healthcare compliance language in 2026-05-06]
- Removed (2025-11-07): 'Results and data we disclosed from prior non-clinical studies and clinical trials may not predict success in later clinical trials...' [expanded in 2026-05-06 to include 'as well as any data disclosed as a result of an interim analysis']
- Removed (2025-11-07): 'Risks Related to Manufacturing RYTELO' section heading changed to 'Risks Related to Manufacturing RYTELO (Imetelstat)' in 2026-05-06
- Removed (2025-11-07): 'If third parties that manufacture RYTELO fail to perform as needed, the commercial and clinical supply of RYTELO could be interrupted or limited, and we may be unable to successfully commercialize RYTELO or conduct or complete current or potential future clinical trials.'
- Removed (2025-11-07): 'Our operating results are unpredictable and may fluctuate. If our operating results are below the expectations of securities analysts or investors, the trading price of our common stock could decline.'
- Removed (2025-11-07): 'We and certain of our current and former officers and directors have been named as defendants in securities class action lawsuits and derivative lawsuits. These lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management's time and attention from our business, and have a material adverse effect on our results of operations. These lawsuits, and any other lawsuits to which we are subject, will be costly to defend or pursue and are uncertain in their outcome.' [reworded in 2026-05-06]
- Reworded:
- 2026-05-06 changed reference structure from 'can be found under "Risk Factors" in Part I, Item 1A of this Report' and 'described under the heading "Risk Factors" below' to consistent 'under "Risk Factors" in Part I, Item 1A of this Report'
- 2026-05-06 revised EU risk factor from 'We will be subject to pricing, drug marketing, post-market and reimbursement regulations in the European Union' to 'We will be subject to pricing and reimbursement regulations in the European Union'
- 2026-05-06 expanded clinical trial risk language to add 'as well as any data disclosed as a result of an interim analysis' to the discussion of prior study results
- 2026-05-06 changed litigation risk language from 'could result in substantial damages, divert management's time and attention from our business, and have a material adverse effect on our results of operations. These lawsuits...will be costly to defend or pursue and are uncertain in their outcome' to 'are costly to defend, could result in substantial damages, divert management's time and attention from our business, and have a material adverse effect on our results of operations'
- 2026-05-06 consolidated multiple commercialization risks into fewer, broader bullets with reorganized groupings
- Notes:
- The text provided for the older filing (2025-11-07) appears to be truncated, ending with 'RIS' suggesting the full section was not captured
- Comparison is limited to the Risk Factor Summary section visible in both filings; full detailed risk factor descriptions that follow may contain additional changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for GERN — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding GERN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 108,324,308
- Reported value $161,403,220
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
GERN had 76,807,284 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
GERN had 12.0% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.9 days to cover at the same settlement.
- Reported short interest (shares) 76,807,284
- Short interest (% of shares outstanding) 12.0%
- Prior settlement (shares) 69,921,486
- Reported change 9.85%
- Days to cover (reported) 9.9
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Acceleron Pharma (part of Merck)
- Incyte (JAK inhibitors for MF)
- Celgene/Bristol Myers Squibb (lenalidomide, azacitadine for MDS)
- Otsuka/Astex (azacitadine)
- Vertex Pharmaceuticals (sickle cell and blood disorders)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GERN vs…
Frequently asked questions
What does GERON CORP (GERN) do?
Geron is a commercial-stage biopharmaceutical company developing telomerase inhibitors to treat blood cancers. Its first-in-class product, RYTELO (imetelstat), was FDA-approved in June 2024 for lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia and received European Commission approval in March 2025. The company is expanding RYTELO's reach through commercial launch in the U.S.
What sector is GERON CORP (GERN) in?
GERON CORP (GERN) is classified in the Health Care sector. Its industry is Oncology / hematologic malignancies biopharmaceutical. It trades on NASDAQ.
Who are GERON CORP's (GERN) competitors?
Notable peers of GERON CORP (GERN) include Acceleron Pharma (part of Merck), Incyte (JAK inhibitors for MF), Celgene/Bristol Myers Squibb (lenalidomide, azacitadine for MDS), Otsuka/Astex (azacitadine) and Vertex Pharmaceuticals (sickle cell and blood disorders). This peer set is informational only — not financial advice.
Is GERON CORP (GERN) overbought or oversold right now?
GERON CORP (GERN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 53, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GERN come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.